0000000000702350

AUTHOR

Simona Losito

showing 2 related works from this author

The Nuclear astrophysics program at n_TOF (CERN)

2017

An important experimental program on Nuclear Astrophysics is being carried out at the n_TOF since several years, in order to address the still open issues in stellar and primordial nucleosynthesis. Several neutron capture reactions relevant to s-process nucleosynthesis have been measured so far, some of which on important branching point radioisotopes. Furthermore, the construction of a second experimental area has recently opened the way to challenging measurements of (n, charged particle) reactions on isotopes of short half-life. The Nuclear Astrophysics program of the n_TOF Collaboration is here described, with emphasis on recent results relevant for stellar nucleosynthesis, stellar neut…

Nuclear reactionAstrofísicaAstrophysics and AstronomyCross-sectionnTOFQC1-999Astrophysics::High Energy Astrophysical PhenomenaNeutron[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]Astrophysics01 natural sciences7. Clean energyn_TOF nuclear astrophysics CERNNuclear physicsPhysics and Astronomy (all)Stellar nucleosynthesisBig Bang nucleosynthesisNucleosynthesis0103 physical sciencesCERNNuclear astrophysicsAstrophysics::Solar and Stellar AstrophysicsNuclear Physics - ExperimentNeutronNeutron induced nuclear reactions010306 general physicsNuclear ExperimentAstrophysics::Galaxy AstrophysicsPhysics:Energies::Energia nuclear [Àrees temàtiques de la UPC]Neutrons:Física [Àrees temàtiques de la UPC]010308 nuclear & particles physicsPhysicsNuclear reactionNeutron capture13. Climate actionNeutron sourceAstrophysics::Earth and Planetary Astrophysics[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]NucleosynthesisNucleosíntesi
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct